DSGN biotech catalysts & pipeline

DESIGN THERAPEUTICS INC · Data as of 2026-09-08

Upcoming catalysts

DT-168 — Initial data

H2 2026

A Phase 2 biomarker trial of DT-168 is ongoing to evaluate safety, tolerability and corneal endothelium biomarkers in FECD patients who are scheduled for corneal transplant surgery, with data anticipated in the second half of 2026.

Source filing

DT-216P2 — Interim data

H2 2026

We anticipate providing an update from the RESTORE-FA trial on the effect of DT-216P2 on endogenous frataxin levels in the second half of 2026.

Source filing

DT-216P2 — Regulatory decision

Q4 2026

Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.

Source filing

DT-168 — Topline data

2027

Data is now expected in 2027 due to a delay in the anticipated supply of DT-168 blow-fill-seal eye droppers.

Source filing

DT-216P2 — Topline data

Q1 2027

Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.

Source filing

DT-818 — Topline data

2027

We anticipate reporting data from this study in 2027.

Source filing

Explore the free biotech catalyst calendar